March 20 (Reuters) - Affimed Nv ::AFFIMED REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR END 2017.Q4 LOSS PER SHARE EUR 0.14.Q4 EARNINGS PER SHARE VIEW EUR -0.17 -- THOMSON REUTERS I/B/E/S.Q4 REVENUE EUR 600,000 VERSUS EUR 1.4 MILLION.Q4 REVENUE VIEW EUR 1.8 MILLION -- THOMSON REUTERS I/B/E/S.OPERATIONS, INCLUDING CLINICAL DEVELOPMENT AND EARLY DEVELOPMENT ACTIVITIES, ARE EXPECTED TO BE FUNDED AT LEAST UNTIL Q4 OF 2019.
Full Article
Feb 13 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.5 MILLION COMMON SHARES PRICED AT $2.00PER SHARE.
Full Article
Feb 12 (Reuters) - Affimed Nv ::AFFIMED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.
Full Article
Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED.AFFIMED NV - DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS.AFFIMED NV - EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA.AFFIMED NV - AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY.AFFIMED NV - AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.
Full Article
Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.
Full Article
Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.
Full Article
Aug 1 (Reuters) - Affimed Nv :Affimed reports financial results for second quarter 2017.Q2 loss per share EUR 0.18.Q2 earnings per share view EUR -0.20 -- Thomson Reuters I/B/E/S.Q2 revenue EUR 500,000 versus EUR 2.1 million.Q2 revenue view EUR 1.2 million -- Thomson Reuters I/B/E/S.Cash and cash equivalents and financial assets totaled EUR 48.9 million as of June 30, 2017.
Full Article
May 17 (Reuters) - Affimed NV :Affimed reports financial results for first quarter 2017.Q1 loss per share eur 0.19.Q1 revenue EUR 400,000 versus EUR 1.9 million.Q1 revenue view EUR 1.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view eur -0.21 -- Thomson Reuters I/B/E/S.Affimed NV - cash and cash equivalents and financial assets totaled eur 53.7 million as of march 31, 2017 compared to eur 44.9 million as of december 31, 2016.
Full Article
Affimed NV : Affimed reports financial results for fourth quarter and year end 2016 . Q4 loss per share eur 0.16 . Q4 earnings per share view EUR -0.29 -- Thomson Reuters I/B/E/S . Q4 revenue EUR 1.4 million versus EUR 1.7 million . Q4 revenue view EUR 1.1 million -- Thomson Reuters I/B/E/S .Affimed NV - including proceeds from offering in January and February 2017, company's operations are expected to be funded at least until end of 2018.
Full Article
Affimed Nv - :Affimed announces closing of public offering of common stock.
Full Article
Earnings vs. 
Estimates